|| ISSN(online): 2589-8698 || ISSN(print): 2589-868X ||

**Available online on http://www.ijmbs.info**

**International Journal of Medical and Biomedical Studies; 2025; 9(4); 37-57**

**Original Research Article**

# Early Breast Cancer - Recent Advances in Imaging and Management

**Anamika Shahi[1], Supriya Sundar Mishra[2], Mahesh Rath[3]**

[1]Assistant Professor, Department of Radiology, Institute of Medical Sciences & SUM Hospital, Bhubaneswar, Odisha, India

[2]Assistant Professor, Department of Radiology, Institute of Medical Sciences & SUM Hospital, Bhubaneswar, Odisha, India

[3]Associate Professor, Department of Community Medicine, Hi-Tech Medical College & Hospital, Bhubaneswar, Odisha, India

**Received: 16-05-2025 / Revised: 18-06-2025 / Accepted: 29-07-2025**
**DOI: https://doi.org/10.32553/ijmbs.v9i4.3097**
**Corresponding author: Supriya Sundar Mishra**
**Conflict of interest: No conflict of interest**

**Abstract:**
Recent advances in the imaging and management of early breast cancer have substantially improved detection rates and patient outcomes, marking a significant evolution in clinical practice. Innovations in imaging modalities, including digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM) and molecular imaging, have enhanced the accuracy and sensitivity of screening, allowing for earlier and more precise identification of breast tumours. The integration of artificial intelligence (AI) and machine learning further augments diagnostic capabilities by automating image analysis and enabling personalized risk assessments. In management, personalized treatment strategies guided by genomic profiling tools, such as Oncotype DX and MammaPrint, have optimized therapeutic approaches, reducing overtreatment and associated side effects.

Advances in minimally invasive surgical techniques, such as sentinel lymph node biopsy (SLNB), oncoplastic surgery and nipple-sparing mastectomy, have improved surgical outcomes by minimizing morbidity and preserving cosmetic results. Meanwhile, innovative radiotherapy approaches, including hypofractionated radiotherapy and intraoperative radiotherapy (IORT), have reduced treatment duration and side effects without compromising efficacy. The development of targeted therapies and immunotherapy has provided new, effective options for specific breast cancer subtypes, enhancing progression-free survival and overall patient care.

Future trends in imaging and management such as the expanded use of AI, new molecular imaging techniques and advances in personalized medicine are expected to further transform early breast cancer care. These innovations hold the potential to improve precision, reduce the treatment burden and enhance patient outcomes. This paper discusses the recent advances, their impact on clinical outcomes and the future directions that may shape the continued evolution of early breast cancer management.

**Keywords:** Early breast cancer, imaging techniques, digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), molecular imaging, artificial intelligence (AI), personalized treatment, genomic profiling, Oncotype DX, MammaPrint, minimally invasive surgery, sentinel lymph node biopsy (SLNB), oncoplastic surgery, nipple-sparing mastectomy, hypofractionated radiotherapy, intraoperative radiotherapy (IORT), targeted therapies, immunotherapy, breast cancer management.

## Introduction

Early breast cancer, defined as breast cancer confined to the breast tissue or nearby lymph nodes without distant metastasis, represents a critical stage where timely detection and intervention can significantly influence patient outcomes. Early stages of breast cancer, classified typically as stage 0, I and II are characterized by localized tumours that have not spread extensively. Detecting breast cancer at this stage is essential, as it dramatically increases the chances of successful treatment, potentially minimizing the need for aggressive therapies, reducing mortality rates and improving the patient's quality of life. As breast cancer continues to be a leading cause of morbidity among women worldwide, ongoing efforts to refine and enhance detection and management strategies are pivotal in improving prognosis and patient care. (1,2)

Recent advancements in both imaging modalities and management approaches have significantly transformed the landscape of early breast cancer detection and treatment. Innovations in imaging techniques, such as digital breast tomosynthesis, contrast-enhanced mammography and molecular imaging, have enhanced the sensitivity and specificity of breast cancer screening, enabling earlier and more precise identification of tumours. Concurrently, the integration of artificial intelligence in diagnostic processes holds potential to further improve accuracy and efficiency in breast cancer imaging. On the management side, personalized medicine approaches, driven by genomic profiling and targeted therapies are increasingly guiding clinical decision-making, alongside the development of minimally invasive surgical techniques, optimized radiotherapy regimens and advanced systemic therapies. (3,4)

The purpose of this paper is to explore the most recent developments in imaging and management of early breast cancer, focusing on their relevance and application within the context of European radiology practice. (5,6) By examining the latest advancements in both imaging technologies and therapeutic strategies, this paper aims to provide a comprehensive overview of how these innovations are reshaping early breast cancer care. Additionally, it will address the impact of these advancements on clinical outcomes, current challenges in their implementation and potential future directions with particular emphasis on considerations pertinent to the European healthcare environment. (7–9)

### Review of Literature

**Traditional Imaging Methods:** Conventional imaging techniques, such as mammography, ultrasound and magnetic resonance imaging (MRI), have been the cornerstone of early breast cancer detection for decades. **Mammography**, utilizing low-dose X-rays, remains the most widely used screening tool for early breast cancer with its ability to detect calcifications and small masses that may indicate malignancy. However, mammography's sensitivity can be significantly reduced in women with dense breast tissue, where overlapping structures may obscure tumours, leading to false negatives.




**Figure 1 - Mammographic Views of a Suspicious Breast Mass**

In such cases, **ultrasound** serves as an adjunct modality, especially useful in evaluating palpable lumps or abnormalities detected on mammography. Ultrasound can distinguish between solid and cystic lesions, though its sensitivity and specificity are highly operator-dependent.

Figure 1 shows - Mammography images of the left breast showing a mass with irregular margins in the 12 o'clock position and indicates a potential malignancy. (A) Medio-lateral oblique (MLO) view and (B) Cranio-caudal (CC) view. The white arrows point to the location of the mass.





**Figure 2 - Ultrasound Imaging of a Breast Mass**
**Figure 3 - Ultrasound-Guided Core Needle Biopsy of a Breast Lesion**

Figure 2 shows an Ultrasound image of a hypoechoic breast mass with irregular margins and posterior acoustic shadowing indicative of a potential malignancy. Figure 3 - Ultrasound also helps in targeting suspicious lesions for biopsy as shown in this image. It is demonstrating a breast lesion (star) undergoing a core needle biopsy with the needle path clearly visualized (arrow) to ensure precise sampling.

Meanwhile, **MRI** is typically employed for high-risk patients, such as those with a strong family history of breast cancer or known BRCA mutations. (7,9,10) MRI provides superior contrast resolution and is effective in detecting tumours in dense breast tissue; however, it is less widely used due to its high cost, limited availability and the potential for false positives due to its sensitivity to benign lesions. Figure 4 shows an MIP image from an abbreviated MRI protocol displaying both whole breasts simultaneously - revealing a small cancer in the right breast (arrow). Figure 5 shows an MRI image of the breast in a high-risk patient with a BRCA1 gene mutation -

showing a small lesion with marked enhancement and irregular margins in the right breast (arrow) - indicative of a malignancy.



**Figure 4 - Abbreviated MRI Protocol Using Maximum Intensity Projection (MIP)**



**Figure 5 - Breast MRI in a High-Risk Patient (BRCA1 Gene Carrier)**

While these traditional methods play a critical role in breast cancer detection, their limitations, such as reduced accuracy in certain populations, dependence on operator skill and the potential for both false positives and negatives, necessitate the development of more advanced imaging technologies. (11–13)




**Figure 6 - Multimodal Imaging of a Breast Lesion**

In the Figure 6 - (A) Mammography in cranio-caudal view shows architectural distortion (arrow). (B) Digital breast tomosynthesis (DBT) enhances visibility of the distortion (arrow). (C) Ultrasound reveals an irregular area of decreased echogenicity (arrow). (D) MRI demonstrates a non-mass-like enhancement in the whole lateral part of the breast (arrow), providing comprehensive assessment across different imaging modalities.

**Recent Advances in Imaging:** Recent technological advancements have led to the development of more sophisticated imaging techniques, enhancing the accuracy and reliability of early breast cancer detection.

**Digital Breast Tomosynthesis (DBT)** has emerged as a significant improvement over traditional mammography by providing three-dimensional imaging of the breast. DBT, also known as 3D mammography, acquires multiple low-dose X-ray images of the breast from different angles, which are then reconstructed into a series of thin slices, allowing for a more detailed examination of the breast tissue. As depicted in Figure 7 Digital breast tomosynthesis (DBT) involves the acquisition of multiple low-dose X-ray images from different angles around the compressed breast, using a moving X-ray tube. These images are then processed and reconstructed into a three-dimensional view to enhance lesion visibility and improve diagnostic accuracy in breast cancer screening.




**Figure 7 - Digital Breast Tomosynthesis Workflow**

Figure 8 shows (A) Conventional mammography and (B) digital breast tomosynthesis (DBT) images of the same breast. The arrows indicate a cancerous lesion that is more clearly visible on the DBT image and demonstrates the enhanced clarity and lesion detectability provided by DBT.




**Figure 8 - Comparison of Mammography and Digital Breast Tomosynthesis (DBT) Imaging**

This technique reduces the impact of overlapping tissue, which is a limitation of conventional 2D mammography, thereby increasing cancer detection rates, especially in women with dense breasts. Additionally, DBT has been shown to reduce recall rates and false positives, improving the overall efficiency and patient experience in breast cancer screening. (4,14)

**Contrast-Enhanced Mammography (CEM)** represents another advancement in breast imaging that combines mammography with the use of an intravenous contrast agent. CEM enhances the visibility of tumours that may not be apparent on standard mammography by highlighting areas of increased blood flow typically associated with malignancies.




**Figure 9 - Temporal Subtraction in Contrast-Enhanced Digital Mammography (CEDM)**

Figure 9 illustrates the temporal subtraction technique in CEDM showing the process from initial mask imaging through post-injection sequence acquisition and subtraction over approximately 5 minutes. The contrast uptake and wash-out graph depict the enhancement pattern over time and aids in the detection of suspicious lesions. This technique is particularly useful for detecting cancers in dense breast tissue and can serve as an alternative to MRI for patients who are contraindicated for MRI or where MRI is not available. Studies have shown that CEM has a high sensitivity comparable to MRI, making it a valuable tool for early detection and preoperative planning. (15–17)

**Molecular Imaging Techniques**, such as **Positron Emission Mammography (PEM)** are being explored for their potential in detecting breast cancer at a molecular level. PEM, a specialized form of positron emission tomography (PET), uses radioactive tracers to visualize metabolic activity in the breast tissue, allowing for the identification of cancerous cells with higher metabolic rates. This technique offers the advantage of detecting cancers that may not be visible on anatomical imaging modalities and provides valuable information on the biological behaviour of the tumour. PEM can be particularly useful in assessing the extent of disease, guiding biopsy and monitoring response to therapy. (7–9,18)

AlSawaftah et al. (2022) provide a comprehensive overview of **microwave imaging (MWI)** as a promising tool for early breast cancer detection. The article discusses the principles, current developments, and potential applications of MWI, which leverages differences in the dielectric properties of breast tissues to detect tumours. (13) It highlights the advantages of MWI, such as being non-invasive, cost-effective, and safe, but also identifies challenges, including limited penetration depth and the need for further research to enhance accuracy and clinical applicability. Future directions focus on developing portable MWI systems, integrating machine learning and improving the dielectric contrast between normal and malignant tissues.

**Artificial Intelligence (AI) and Machine Learning** are increasingly being integrated into breast imaging to enhance diagnostic accuracy and efficiency. AI algorithms, trained on vast datasets of breast images, can assist radiologists by automatically identifying suspicious areas, quantifying breast density and even predicting an individual's risk of developing breast cancer. Figure 10 shows (a) Mediolateral view of the right breast in an asymptomatic woman showing multiple masses (black arrows) with the largest mass in the superior breast (white arrow). (b) Deep learning model identifies the superior mass as suspicious (colour overlay in red)




**Figure 10 - Application of Deep Learning Model in Mammography Screening**

These tools can help reduce human error, standardize image interpretation and optimize screening strategies by identifying high-risk individuals who may benefit from more frequent monitoring or additional imaging modalities. Moreover, AI-driven technologies have the potential to reduce workload and increase productivity in radiology departments, ultimately improving patient outcomes. (19–22)

**Comparison of Imaging Modalities:** The recent advances in imaging modalities for early breast cancer detection each offer unique benefits and limitations. **Digital Breast Tomosynthesis (DBT)** improves upon the specificity and sensitivity of conventional mammography, particularly in women with dense breasts, but may still miss certain cancers that do not present with typical architectural distortions. **Contrast-Enhanced Mammography (CEM)** provides a high sensitivity comparable to MRI while being more accessible and cost-effective; however, it involves the use of contrast agents, which may not be suitable for all patients. **Molecular imaging techniques** like **PEM** offer detailed insights into the metabolic activity of breast lesions but are not yet widely available and may involve higher costs and radiation exposure compared to other modalities. Finally, the integration of **AI and machine learning** into breast imaging holds promise for enhancing accuracy, reducing false positives and personalizing screening protocols, but these technologies are still in the early stages of clinical application and require robust validation through extensive studies. (23–29)




**Figure 11 - Flowchart Representation of Diagnostic Tests for Early Breast Cancer Detection**

The flowchart diagram in Figure 11 provides a structured visualization of the various diagnostic tests available for early breast cancer detection, outlining the sequential decision-making process based on different imaging modalities. Beginning with the central point, "Diagnostic Tests for Early Breast Cancer Detection," the flow branches into key diagnostic categories such as Mammography, Ultrasound, MRI, Molecular Imaging and Microwave Imaging (MWI). Each primary category further divides into specialized techniques, such as Digital Mammography, Digital Breast Tomosynthesis (DBT), Contrast-Enhanced Mammography (CEM), Elastography and advanced MRI techniques like DCE-MRI and DWI. The diagram also includes future directions such as machine learning integration with MWI, highlighting the decision points and pathways clinicians may follow based on patient needs and clinical scenarios. This visual representation helps clarify the complex diagnostic process, ensuring a comprehensive understanding of the various tools and methods used in breast cancer detection.

The choice of imaging modality must be tailored to the individual patient's clinical scenario, considering factors such as breast density, personal and family history and availability of advanced imaging technologies. Combining multiple imaging approaches may provide the most comprehensive assessment and ensure early and accurate detection of breast cancer while minimizing unnecessary interventions and optimizing patient care outcomes.

## Advances in Management of Early Breast Cancer

**Personalized Treatment Approaches:** Recent advances in genomic and molecular profiling have significantly enhanced the personalization of treatment for early breast cancer. **Genomic and molecular profiling**, such as Oncotype DX and MammaPrint, provide detailed analyses of the genetic makeup of breast cancer tumours, assessing the expression of multiple genes that can predict the risk of recurrence and potential response to therapy. These tests help clinicians tailor treatment strategies by identifying patients who are more likely to benefit from chemotherapy versus those who can safely avoid it. For instance, Oncotype DX evaluates 21 genes within a tumour to produce a recurrence score that guides the use of adjuvant chemotherapy in hormone receptor-positive, HER2-negative early breast cancer. Similarly, MammaPrint assesses 70 genes to stratify patients into high or low risk for recurrence. These profiling tools enable a more individualized approach, minimizing unnecessary exposure to chemotherapy and its associated toxicities and optimizing therapeutic outcomes based on the tumour’s specific biological characteristics. (3,7,10)

**Minimally Invasive and Conservative Techniques:** Minimally invasive and conservative surgical techniques have also seen significant advancements in the management of early breast cancer, aiming to reduce morbidity and improve cosmetic outcomes without compromising oncologic safety. **Sentinel Lymph Node Biopsy (SLNB)** has largely replaced the more extensive axillary lymph node dissection (ALND) for patients with clinically negative axillary nodes. SLNB involves the removal of a few sentinel lymph nodes, which are the first nodes to which cancer cells are likely to spread from the primary tumour. (30,31) If these nodes are free of cancer, further lymph node surgery can often be avoided. This technique has proven to reduce the risk of complications such as lymphedema, pain and reduced arm mobility, which are more common with ALND while maintaining equivalent survival outcomes in appropriate patients.




**Figure 12 - Flowchart of Advances in Management of Early Breast Cancer**

In addition to SLNB, there have been **advances in surgical techniques** such as oncoplastic surgery and nipple-sparing mastectomy. **Oncoplastic surgery** combines tumour removal with plastic surgery techniques, allowing for wider excision of the tumour while maintaining or even enhancing breast appearance. This approach minimizes the psychological and aesthetic impacts of surgery and has become an essential part of breast-conserving surgery. (32) Similarly, **nipple-sparing mastectomy** involves removing the breast tissue while preserving the nipple-areolar complex, offering superior cosmetic results and psychological benefits without compromising oncologic safety in carefully selected patients. (33,34) The flowchart (Figure-12) illustrates the key advances in the management of early breast cancer, focusing on personalized treatment approaches and minimally invasive surgical techniques. Under personalized treatment, genomic and molecular profiling tools, such as Oncotype DX and MammaPrint, guide clinicians in tailoring therapies based on a patient's unique tumour characteristics, reducing unnecessary chemotherapy and optimizing outcomes. (35,36) The minimally invasive techniques include Sentinel Lymph Node Biopsy (SLNB), which minimizes the need for extensive lymph node surgery and advanced surgical methods like oncoplastic surgery and nipple-sparing mastectomy, which aim to preserve or enhance breast aesthetics without compromising oncologic safety. (4,37)

**Radiotherapy Advances**

Advancements in radiotherapy have focused on reducing the treatment burden while maintaining its effectiveness. **Hypofractionated radiotherapy** is a technique that delivers higher doses of radiation over a shorter period. Recent findings have demonstrated that hypofractionated regimens, typically given over 3 to 4 weeks are as effective as the traditional 5- to 7-week regimens in terms of local control and survival with no increase in side effects. This approach is particularly beneficial for patients as it reduces the duration and inconvenience of treatment, improves patient compliance and lowers healthcare costs. (29,38,39)

Another innovative technique is **Intraoperative Radiotherapy (IORT)**, which involves delivering a single, high dose of radiation to the tumour bed during surgery, immediately following tumour excision. IORT has the potential to replace several weeks of conventional postoperative radiation for select patients with early-stage breast cancer. This method has demonstrated comparable outcomes in local recurrence rates for certain patient groups while minimizing radiation exposure to surrounding healthy tissues and organs. IORT also offers the advantage of completing both surgery and radiotherapy in a single session, enhancing patient convenience and reducing overall treatment time. (40,41)

**Systemic Therapies:** Systemic therapies for early breast cancer have advanced significantly, particularly with the development of targeted therapies and immunotherapy. **Targeted therapies** focus on specific molecular pathways involved in cancer growth and progression. Agents such as **PARP inhibitors** (e.g., olaparib) have shown efficacy in treating BRCA-mutated breast cancers by exploiting defects in DNA repair mechanisms. (42,43) **CDK4/6 inhibitors** (e.g., palbociclib, ribociclib) have also become a standard component of therapy for hormone receptor-positive, HER2-negative breast cancer, improving progression-free survival when added to endocrine therapy. These targeted therapies are tailored to specific molecular characteristics of the tumour, offering more personalized and potentially less toxic treatment options. (44,45)

**Immunotherapy**, which harnesses the body's immune system to recognize and destroy cancer cells, has emerged as a promising approach for certain types of breast cancer. Agents such as checkpoint inhibitors (e.g., pembrolizumab) are being explored in combination with other treatments for early breast cancer, particularly in patients with high-risk features or triple-negative breast cancer. Although still under investigation, early studies suggest that immunotherapy may improve outcomes by enhancing the immune response against cancer cells. **Endocrine therapy optimization** has also evolved, particularly for hormone receptor-positive early breast cancer. Recent strategies focus on optimizing the duration and type of endocrine therapy to maximize benefit while minimizing side effects. Extended adjuvant therapy, involving the continuation of endocrine therapy beyond the standard five years, has shown promise in reducing the risk of late recurrences in selected patients. Additionally, switching between different types of endocrine therapy, such as from tamoxifen to an aromatase inhibitor, has been shown to further reduce recurrence risk. As provided in Figure 3, ongoing research aims to refine these strategies based on patient-specific factors - including genetic predispositions and tumour biology - to tailor endocrine therapy more effectively. (6,46)




**Figure 13 - Advances in Radiotherapy and Systemic Therapies for Early Breast Cancer**

These advancements as summarized and shown in Figure 13 assist in the management of early breast cancer and reflect a paradigm shift toward more personalized, less invasive and increasingly targeted approaches, enhancing both clinical outcomes and patient quality of life. As research continues to evolve, the integration of these advances into routine clinical practice will be essential to further improve the prognosis and care of patients with early breast cancer.

## Impact of Recent Advances on Clinical Outcomes

**Survival Rates and Quality of Life:** The recent advances in the management of early breast cancer have significantly impacted both survival rates and patients' quality of life. Improved imaging technologies, personalized treatment strategies and minimally invasive procedures have all contributed to better clinical outcomes. **Survival rates** for early-stage breast cancer have increased markedly due to earlier and more accurate detection and the application of targeted therapies tailored to the specific molecular characteristics of the tumour. For example, genomic and molecular profiling tools, such as Oncotype DX and MammaPrint, have allowed for more precise identification of patients who will benefit from chemotherapy, thereby improving overall survival rates. Clinical trials have demonstrated that the use of these tools can reduce the risk of recurrence by guiding the appropriate use of adjuvant therapies, ensuring that patients receive the most effective treatment based on their individual risk profiles. (35,36)

The adoption of **minimally invasive surgical techniques** like sentinel lymph node biopsy (SLNB), oncoplastic surgery and nipple-sparing mastectomy has also improved patient outcomes by reducing surgical morbidity and preserving cosmetic appearance. These advances have been associated with lower complication rates, reduced pain and faster recovery times, thereby improving patients' quality of life during and after treatment. Additionally, innovations in **radiotherapy**, such as hypofractionated radiotherapy and intraoperative radiotherapy (IORT), have shortened treatment durations and reduced the burden of daily hospital visits, without compromising efficacy. These approaches have been shown to maintain or improve local control rates and overall survival while minimizing side effects, contributing positively to patients' overall well-being. (47)

Moreover, the development of **targeted therapies** and **immunotherapy** has provided more effective treatment options for specific subtypes of breast cancer, such as HER2-positive and triple-negative breast cancers, which were previously associated with poorer outcomes. These therapies have demonstrated significant improvements in disease-free and overall survival rates in clinical trials, particularly for patients with high-risk features. The optimization of **endocrine therapy** has further contributed to prolonged survival and reduced recurrence rates in hormone receptor-positive breast cancer. Extended adjuvant therapy and strategic switching between different endocrine agents have been shown to decrease the risk of late recurrences, thus enhancing long-term outcomes.

Overall, the integration of these advances into clinical practice has resulted in a holistic improvement in both **survival rates** and **quality of life** for patients with early breast cancer. As these innovations continue to be refined and adopted, further improvements in clinical outcomes are anticipated.

**Reducing Overtreatment:** Efforts to balance effective treatment with minimizing overtreatment have become a critical focus in the management of early breast cancer. Historically, many patients underwent extensive surgery, prolonged radiotherapy and chemotherapy regimens, leading to substantial physical, emotional and financial burdens. However, recent advances aim to tailor treatment more closely to the individual patient’s risk profile, thereby reducing unnecessary interventions and their associated side effects.

**Genomic and molecular profiling** tools have been instrumental in identifying patients who are unlikely to benefit from chemotherapy, allowing for a more conservative approach that spares these patients from the toxicities associated with systemic treatments. For instance, the TAILORx trial demonstrated that women with a low to intermediate Oncotype DX recurrence score could safely forgo chemotherapy without compromising their long-term outcomes. This shift towards more personalized care reduces the incidence of overtreatment and the resultant side effects, such as cardiotoxicity, neuropathy and fatigue, which significantly affect quality of life. (48,49)

In addition, the use of **minimally invasive techniques**, such as sentinel lymph node biopsy (SLNB) instead of axillary lymph node dissection (ALND), has reduced the extent of surgery required for many patients, minimizing complications like lymphedema and nerve damage. **Oncoplastic surgery** and **nipple-sparing mastectomy** provide effective cancer control while preserving breast aesthetics, reducing the psychological impact of surgery and the need for extensive reconstructive procedures.

The evolution of **radiotherapy** has also emphasized the importance of reducing treatment intensity without compromising efficacy. Hypofractionated radiotherapy has become a standard of care for many patients, reducing the number of sessions required and the associated side effects. **Intraoperative radiotherapy (IORT)** further minimizes treatment burden by providing a single dose of radiation at the time of surgery, potentially eliminating the need for several weeks of postoperative radiotherapy in suitable candidates.

Finally, optimizing **endocrine therapy** for hormone receptor-positive breast cancer has focused on balancing the benefits of extended treatment duration against the risks of side effects, such as osteoporosis and cardiovascular events. Ongoing research aims to refine these strategies to provide the maximum benefit with the least harm as shown in Figure 14.




**Figure 14 - Impact of Recent Advances on Clinical Outcomes in Early Breast Cancer**

These efforts to reduce overtreatment in early breast cancer management reflect a broader shift toward patient-centred care, where treatment decisions are tailored to individual risk profiles and preferences. By focusing on minimizing unnecessary interventions and their associated side effects, clinicians can achieve a better balance between effective cancer control and preserving the patient's quality of life. As evidence continues to accumulate, these strategies will likely become increasingly central to the management of early breast cancer, ensuring that patients receive the most appropriate, effective and least burdensome care possible.

## Current Challenges and Future Directions

**Barriers to Implementation:** The adoption of new imaging and management techniques for early breast cancer faces several significant challenges. One of the primary barriers is **cost**. Advanced imaging technologies, such as Digital Breast Tomosynthesis (DBT), Contrast-Enhanced Mammography (CEM) and Molecular Imaging techniques like Positron Emission Mammography (PEM), often require substantial financial investment in new equipment, software and infrastructure. (50) Additionally, the costs associated with developing and integrating Artificial Intelligence (AI) tools for imaging analysis can be prohibitive for many healthcare facilities, particularly those in low-resource settings. These costs are compounded by the need for ongoing maintenance, upgrades and software updates, which can strain healthcare budgets.

**Accessibility** is another major challenge. Even where advanced imaging technologies and personalized treatment options are available, they may not be accessible to all patients. Factors such as geographical location, healthcare infrastructure and socioeconomic status can limit patient access to these innovations. For example, rural or underserved areas may lack the specialized facilities and equipment necessary for advanced breast imaging and management, resulting in disparities in care. Furthermore, these advanced techniques often require **specialized training** for healthcare providers. Radiologists, oncologists and surgeons must be proficient in interpreting new imaging modalities and utilizing novel therapeutic strategies. However, there is often a lack of standardized training programs and resources to adequately prepare healthcare professionals, which can delay the implementation of these advancements into routine clinical practice.

**Future Trends:** Looking forward, several promising trends are likely to shape the future of imaging and management for early breast cancer as summarized in Figure 15. In the realm of imaging, **Artificial Intelligence (AI) and machine learning** are expected to play an increasingly prominent role. AI has the potential to enhance the accuracy and efficiency of breast cancer detection by automatically analyzing large datasets of breast images, identifying patterns that may be imperceptible to human eyes and reducing the rate of false positives and negatives. Future AI developments may also involve predictive modelling to assess an individual's risk of developing breast cancer, allowing for more personalized screening protocols. Additionally, new **molecular imaging techniques** are likely to emerge, offering even more precise methods for detecting cancer at a molecular level, potentially before tumours become visible on traditional imaging modalities.




**Figure 15 - Future Trends in Imaging and Management of Early Breast Cancer**

In terms of management, the focus on **personalized medicine** is expected to continue growing with advances in genomic and molecular profiling leading to even more tailored treatment approaches. Novel drug therapies, such as **next-generation targeted agents** and **immunotherapies** are being developed to target specific molecular pathways involved in breast cancer. These therapies aim to improve efficacy while reducing side effects by targeting cancer cells more precisely, minimizing damage to surrounding healthy tissue. Furthermore, new biomarkers and genetic tests may emerge, allowing for the identification of patients who would benefit most from specific treatments, thereby enhancing the precision of therapeutic strategies.

**European Context:** In the European setting, the implementation of new imaging and management techniques faces unique challenges and opportunities. **Regulatory differences** between countries can create barriers to the adoption of innovative technologies. The European Medicines Agency (EMA) and other regulatory bodies have stringent requirements for the approval of new diagnostic tools and therapies, which can slow down their introduction into clinical practice. Additionally, differences in national health policies, reimbursement structures and funding mechanisms can impact the availability and adoption of these new technologies across Europe. Some countries may have well-established national screening programs and comprehensive healthcare coverage that facilitate the adoption of advanced imaging and personalized treatment options while others may face financial and infrastructural limitations. (6,46,51)

**Healthcare system variability** within Europe is another factor that affects the uptake of new breast cancer management strategies. While some countries have centralized healthcare systems that enable coordinated care and rapid dissemination of new practices, others have more fragmented systems that can impede the implementation of uniform guidelines and innovations. Furthermore, there are **regional disparities** in access to care with differences in the availability of specialized breast cancer services, particularly in rural or less affluent regions. These disparities may lead to unequal access to new imaging and management techniques, creating gaps in care quality and outcomes.

However, the European context also offers several opportunities. The presence of robust healthcare infrastructures in many countries, coupled with a strong emphasis on research and innovation, provides a fertile ground for the development and testing of new imaging technologies and personalized therapies. European collaborative research initiatives, such as those funded by the European Union (EU), can facilitate multicentre trials, data sharing and the rapid dissemination of best practices. Moreover, Europe's diverse population provides a valuable setting for studying the effectiveness of new interventions across different genetic, ethnic and socioeconomic groups, helping to refine personalized approaches to breast cancer care.

**Summary of the Paper:**

Recent advances in imaging and management have significantly transformed the landscape of early breast cancer detection and treatment. Improved imaging techniques, such as digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM) and molecular imaging, have enhanced the sensitivity and specificity of breast cancer screening, enabling earlier and more accurate tumour identification. The integration of artificial intelligence in diagnostic processes further promises to improve accuracy and efficiency by automating the analysis of breast images and predicting an individual's risk of developing breast cancer. In management, personalized treatment approaches driven by genomic profiling tools, like Oncotype DX and MammaPrint, have allowed for more tailored therapies, reducing unnecessary exposure to chemotherapy and optimizing patient outcomes.

Advances in minimally invasive surgical techniques, such as sentinel lymph node biopsy (SLNB), oncoplastic surgery and nipple-sparing mastectomy, have reduced surgical morbidity while preserving cosmetic outcomes, thus improving patients' quality of life. Innovations in radiotherapy, including hypofractionated radiotherapy and intraoperative radiotherapy (IORT), have shortened treatment durations and minimized side effects, offering comparable survival outcomes with less treatment burden. Additionally, targeted therapies and immunotherapy have emerged as promising options for specific subtypes of breast cancer, providing more effective treatments that are tailored to the molecular characteristics of tumours.

Looking ahead, several promising trends, such as the use of artificial intelligence, new molecular imaging techniques and advances in personalized medicine are likely to further shape the future of early breast cancer care. These trends include the development of novel drug therapies, next-generation targeted agents and the discovery of new biomarkers to enhance precision in treatment strategies. The integration of these advances into clinical practice will continue to improve survival rates and quality of life for patients while also addressing challenges related to cost, accessibility and implementation in diverse healthcare settings.

## Conclusion

The recent advancements in imaging and management of early breast cancer have led to a paradigm shift toward more personalized, less invasive and increasingly targeted approaches. These innovations have resulted in significant improvements in both clinical outcomes and patient quality of life by enabling earlier detection, more tailored therapies, and reduced treatment burden. While challenges remain in terms of cost, accessibility, and integration into routine practice, particularly within the European context, future trends in artificial intelligence, molecular imaging and personalized medicine hold promise for further enhancing patient care. As research continues to evolve, fostering collaboration across healthcare systems and disciplines will be essential to ensuring equitable access to the latest advances in breast cancer management, ultimately improving the prognosis and quality of care for patients worldwide. In conclusion we surmise that while there are significant challenges to the implementation of new imaging and management techniques for early breast cancer, future advancements in AI, molecular imaging and personalized medicine hold promise for further improving outcomes. The unique regulatory, healthcare, and demographic landscape in Europe presents both obstacles and opportunities for the adoption of these innovations, highlighting the need for tailored strategies that address local needs and contexts. As the field continues to evolve, fostering collaboration across borders and disciplines will be essential to ensuring equitable access to the latest advances in breast cancer care.

## References

1. Toi M, Kataoka M, Velaga R, Benson JR, Takada M, Jatoi I. Advances in Breast Cancer Screening: Precision, Imaging, and Harms. In: Screening and Risk Reduction Strategies for Breast Cancer: Imaging Modality and Risk-Reduction Approaches. 2023.
2. Vaidya V, Bhandary V, Vishwakarma P, Qureshi F. Biomarkers for Early Detection of Lung Cancer. In: Research Developments in Medicine and Medical Science Vol 3. 2023.
3. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: A review. Vol. 10, Journal of Clinical Oncology. 1992.
4. Alhalmi A, Beg S, Almalki WH, Alghamdi S, Kohli K. Recent Advances in Nanotechnology-Based Targeted Therapeutics for Breast Cancer Management. Curr Drug Metab. 2022;23(8).
5. Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Vol. 17, Nature Reviews Clinical Oncology. 2020.
6. Dimitrova M, Lakic D, Petrova G, Bešlija S, Culig J. Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries. SAGE Open Med. 2020;8.
7. Alcantara D, Leal MP, García-Bocanegra I, García-Martín ML. Molecular imaging of breast cancer: Present and future directions. Vol. 2, Frontiers in Chemistry. 2014.
8. Miladinova D. Molecular Imaging in Breast Cancer. Vol. 53, Nuclear Medicine and Molecular Imaging. 2019.
9. Munnink THO, Nagengast WB, Brouwers AH, Schröder CP, Hospers GA, Hooge MNL de, et al. Molecular imaging of breast cancer. Breast. 2009;18(SUPPL.3).
10. Boers J, de Vries EFJ, Glaudemans AWJM, Hospers GAP, Schröder CP. Application of PET Tracers in Molecular Imaging for Breast Cancer.

Vol. 22, Current Oncology Reports. 2020.
11. Wang L. Early diagnosis of breast cancer. Sensors (Switzerland). 2017;17(7).
12. Ouyang Y, Zhou Z, Wu W, Tian J, Xu F, Wu S, et al. A review of ultrasound detection methods for breast microcalcification. Vol. 16, Mathematical Biosciences and Engineering. 2019.
13. Alsawaftah N, El-Abed S, Dhou S, Zakaria A. Microwave Imaging for Early Breast Cancer Detection: Current State, Challenges, and Future Directions. Vol. 8, Journal of Imaging. 2022.
14. Bhushan A, Gonsalves A, Menon JU. Current state of breast cancer diagnosis, treatment, and theranostics. Vol. 13, Pharmaceutics. 2021.
15. Perry H, Phillips J, Dialani V, Slanetz PJ, Fein-Zachary VJ, Karimova EJ, et al. Contrast-enhanced mammography: A systematic guide to interpretation and reporting. Vol. 212, American Journal of Roentgenology. 2019.
16. Gelardi F, Ragaini EM, Sollini M, Bernardi D, Chiti A. Contrast-Enhanced Mammography versus Breast Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Vol. 12, Diagnostics. 2022.
17. Coffey K, Jochelson MS. Contrast-enhanced mammography in breast cancer screening. Vol. 156, European Journal of Radiology. 2022.
18. Ming Y, Wu N, Qian T, Li X, Wan DQ, Li C, et al. Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer. Vol. 10, Frontiers in Oncology. 2020.
19. Hickman SE, Baxter GC, Gilbert FJ. Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations. Vol. 125, British Journal of Cancer. 2021.
20. You C, Shen Y, Sun S, Zhou J, Li J, Su G, et al. Artificial intelligence in breast imaging: Current situation and clinical challenges. Vol. 3, Exploration. 2023.
21. Bahl M. Updates in Artificial Intelligence for Breast Imaging. Semin Roentgenol. 2022;57(2).
22. Ozcan BB, Patel BK, Banerjee I, Dogan BE. Artificial Intelligence in Breast Imaging: Challenges of Integration into Clinical Practice. Vol. 5, Journal of Breast Imaging. 2023.
23. Mendelson EB. Artificial intelligence in breast imaging: Potentials and limitations. Vol. 212, American Journal of Roentgenology. 2019.
24. Le EPV, Wang Y, Huang Y, Hickman S, Gilbert FJ. Artificial intelligence in breast imaging. Vol. 74, Clinical Radiology. 2019.
25. Kornecki A. Current Status of Contrast Enhanced Mammography: A Comprehensive Review. Vol. 73, Canadian Association of Radiologists Journal. 2022.
26. Yang ML, Bhimani C, Roth R, Germaine P. Contrast enhanced mammography: focus on frequently encountered benign and malignant diagnoses. Vol. 23, Cancer Imaging. 2023.
27. Sogani J, Mango VL, Keating D, Sung JS, Jochelson MS. Contrast-enhanced mammography: past, present, and future. Vol. 69, Clinical Imaging. 2021.
28. Azria D, Lemanski C. Intraoperative radiotherapy for breast cancer. Vol. 383, The Lancet. 2014.
29. Sedlmayer F, Reitsamer R, Wenz F, Sperk E, Fussl C, Kaiser J, et al. Intraoperative radiotherapy (IORT) as boost in breast cancer. Vol. 12, Radiation oncology (London, England). 2017.
30. van Akkooi ACJ, Schadendorf D, Eggermont AMM. Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. Eur J Cancer. 2023;182.
31. Wang ZH, Gang TR, Wu SS, Lu C, Gao GX, Xu W, et al. Single-port endoscopic-sentinel lymph node biopsy

combined with indocyanine green and carbon nanoparticles in breast cancer. Surg Endosc. 2023;37(10).
32. Enright K, Desai T, Sutradhar R, Gonzalez A, Powis M, Taback N, et al. Factors associated with imaging in patients with early breast cancer after initial treatment. Current Oncology. 2018;25(2).
33. Filipe MD, de Bock E, Postma EL, Bastian OW, Schellekens PPA, Vriens MR, et al. Robotic nipple-sparing mastectomy complication rate compared to traditional nipple-sparing mastectomy: a systematic review and meta-analysis. Vol. 16, Journal of Robotic Surgery. 2022.
34. Zaborowski AM, Roe S, Rothwell J, Evoy D, Geraghty J, McCartan D, et al. A systematic review of oncological outcomes after nipple-sparing mastectomy for breast cancer. Vol. 127, Journal of Surgical Oncology. 2023.
35. Yao K, Tong CY, Cheng C. A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction. Sci Rep. 2022;12(1).
36. Xin L, Liu YH, Martin TA, Jiang WG. The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint. World J Oncol. 2017;8(2).
37. Gupta P, Neupane YR, Parvez S, Kohli K. Recent advances in targeted nanotherapeutic approaches for breast cancer management. Vol. 16, Nanomedicine. 2021.
38. Piotrowski I, Kulcenty K, Wichtowski M, Murawa D, Suchorska W. Intraoperative Radiotherapy of Breast Cancer and Its Biological Effects. Vol. 12, Breast Care. 2017.
39. Harris EER, Small W. Intraoperative radiotherapy for breast cancer. Vol. 7, Frontiers in Oncology. 2017.
40. Guillerm S ophie, Bourstyn E, Itti R, Cahen-Doidy L, Quéro L, Labidi M, et al. Intraoperative Radiotherapy for Breast Cancer in Elderly Women. Clin Breast Cancer. 2022;22(1).
41. Yang Y, Hou X, Kong S, Zha Z, Huang M, Li C, et al. Intraoperative radiotherapy in breast cancer: Alterations to the tumor microenvironment and subsequent biological outcomes (Review). Mol Med Rep. 2023;28(6).
42. Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Vol. 8, Frontiers in Cell and Developmental Biology. 2020.
43. Wang SSY, Jie YE, Cheng SW, Ling GL, Ming HVY. PARP Inhibitors in Breast and Ovarian Cancer. Vol. 15, Cancers. 2023.
44. Pandey K, An HJ, Kim SK, Lee SA, Kim S, Lim SM, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Vol. 145, International Journal of Cancer. 2019.
45. Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Vol. 45, Cancer Treatment Reviews. 2016.
46. Cardoso F, McCartney A, Ponti A, Marotti L, Vrieling C, Eniu A, et al. European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care. Eur J Cancer. 2023;187.
47. Elfgen C, Güth U, Gruber G, Birrer S, Bjelic-Radisic V, Fleisch M, et al. Breast-conserving surgery with intraoperative radiotherapy in recurrent breast cancer: the patient's perspective. Breast Cancer. 2020;27(6).
48. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. Vol. 26, Journal of Clinical Oncology. 2008.
49. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast

Cancer. New England Journal of Medicine. 2018;379(2).
50. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. Journal of Clinical Oncology. 2000;18(20).
51. Biganzoli L, Cardoso F, Beishon M, Cameron D, Cataliotti L, Coles CE, et al. The requirements of a specialist breast centre. In: Breast. 2020.